NCT06561620View on ClinicalTrials.gov

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

592

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2029

Conditions
3-year Disease-free Survival
Interventions
DRUG

Befotertinib

Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.

Trial Locations (1)

200032

RECRUITING

Fudan University Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER